David Li is the co-founder and CEO of Meliora Therapeutics, a newly launched ML driven and mechanism focused oncology therapeutics company co-founded with Jason Sheltzer (faculty at Yale) and Joan Smith. David previously was Chief Business Officer at Everest Detection, a cancer early detection liquid biopsy company, and employee #6 and commercial leader at Benchling, a life science software platform valued at $6bn. He started his career at Goldman Sachs and KKR where he completed over $10bn in enterprise value of announced transactions in the biotech and biopharma industry. David is a graduate of the Vagelos Life Sciences and Management dual degree program at Penn.

© 2022 BioFutureTM. All Rights Reserved

Produced by